Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII

被引:1
|
作者
Gui Yinli [1 ]
Bai Wei [1 ]
Xu Jian [13 ]
Duan Xinwang [13 ]
Zhan Feng [13 ]
Zhao Chen [13 ]
Jiang Zhenyu [13 ]
Li Zhijun [13 ]
Wu Lijun [13 ]
Liu Shengyun [13 ]
Yang Min [39 ]
Wei Wei [13 ]
Wang Ziqian [1 ]
Zhao Jiuliang [1 ]
Wang Qian [1 ]
Leng Xiaomei [1 ]
Tian Xinping [1 ]
Li Mengtao [1 ]
Zhao Yan [1 ]
Zeng Xiaofeng [1 ]
CSTAR co-authors
机构
[1] Department of Rheumatology
[2] First Affiliated Hospital of Kunming Medical University  15. Kunming  16. Yunnan 650032 
[3] Department of Rheumatology and Clinical Immunology
[4] Chinese Academy of Medical Sciences &amp  3. Peking Union Medical College  4. National Clinical Research Center for Dermatologic and Immunologic
[5] Department of Rheumatology and Immunology
[6] Nanfang Hospital  41. Southern Medical University  42. Guangzhou  43. Guangdong 510515 
关键词
Systemic lupus erythematosus; Lupus nephritis; Sex; End-stage renal disease; Sex differences;
D O I
暂无
中图分类号
R593.241 [];
学科分类号
1002 ; 100201 ;
摘要
Background: The onset and clinical presentation of systemic lupus erythematosus (SLE) are sex-related. Few studies have investigated the distinctions in clinical characteristics and treatment preferences in male and female SLE patients in the initial cohort. This study aimed to improve the understanding of Chinese SLE patients by characterizing the different sexes of SLE patients in the inception cohort.Methods: Based on the initial patient cohort established by the Chinese SLE Treatment and Research Group, a total of 8713 patients (795 men and 7918 women) with newly diagnosed SLE were enrolled between April 2009 and March 2021. Of these, 2900 patients (347 men and 2553 women) were eligible for lupus nephritis (LN). A cross-sectional analysis of the baseline demographic characteristics, clinical manifestations, laboratory parameters, organ damage, initial treatment regimens, and renal pathology classification was performed according to sex.Results: In the SLE group, as compared to female patients, male patients had a later age of onset (malevs. female: 37.0 ± 15.8 yearsvs. 35.1 ± 13.7 years,P = 0.006) and a higher SLE International Collaborative Clinic/American College of Rheumatology damage index score (malevs. female: 0.47 ± 1.13vs. 0.34 ± 0.81,P = 0.015), LN (malevs. female: 43.6%vs. 32.2%,P < 0.001), fever (malevs. female: 18.0%vs. 14.6%,P = 0.010), thrombocytopenia (malevs. female: 21.4%vs. 18.5%,P = 0.050), serositis (malevs. female: 14.7%vs. 11.7%,P= 0.013), renal damage (malevs. female: 11.1%vs. 7.4%,P < 0.001), and treatment with cyclophosphamide (CYC) (P < 0.001). The frequency of leukopenia (malevs. female: 20.5%vs. 25.4%,P = 0.002) and arthritis (malevs. female: 22.0%vs. 29.9%,P < 0.001) was less in male patients with SLE. In LN, no differences were observed in disease duration, SLE Disease Activity Index score, renal biopsy pathological typing, or 24-h urine protein quantification among the sexes. In comparisons with female patients with LN, male patients had later onset ages (P = 0.026), high serum creatinine (P < 0.001), higher end-stage renal failure rates (P = 0.002), musculoskeletal damage (P = 0.023), cardiovascular impairment (P = 0.009), and CYC use (P = 0.001); while leukopenia (P = 0.017), arthritis (P = 0.014), and mycophenolate usage (P = 0.013) rates were lower.Conclusions: Male SLE patients had more severe organ damage and a higher LN incidence compared with female SLE patients; therefore, they may require more aggressive initial treatment compared to female patients.
引用
收藏
相关论文
共 50 条
  • [1] Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
    Gui, Yinli
    Bai, Wei
    Xu, Jian
    Duan, Xinwang
    Zhan, Feng
    Zhao, Chen
    Jiang, Zhenyu
    Li, Zhijun
    Wu, Lijun
    Liu, Shengyun
    Yang, Min
    Wei, Wei
    Wang, Ziqian
    Zhao, Jiuliang
    Wang, Qian
    Leng, Xiaomei
    Tian, Xinping
    Li, Mengtao
    Zhao, Yan
    Zeng, Xiaofeng
    [J]. CHINESE MEDICAL JOURNAL, 2022, 135 (18) : 2191 - 2199
  • [2] Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
    Jiang, N.
    Li, M.
    Zhang, M.
    Xu, J.
    Jiang, L.
    Gong, L.
    Wu, F.
    Gu, J.
    Zhao, J.
    Xiang, Y.
    Wang, Z.
    Zhao, Y.
    Zeng, X.
    [J]. PLOS ONE, 2019, 14 (11):
  • [3] Chinese SLE Treatment and Research group (CSTAR) registry: V. gender impact on Chinese patients with systemic lupus erythematosus
    Zhang, S.
    Su, J.
    Li, X.
    Zhang, X.
    Liu, S.
    Wu, L.
    Ma, L.
    Bi, L.
    Zuo, X.
    Sun, L.
    Huang, C.
    Zhao, J.
    Li, M.
    Zeng, X.
    [J]. LUPUS, 2015, 24 (12) : 1267 - 1275
  • [4] Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus
    Zhao, J.
    Bai, W.
    Zhu, P.
    Zhang, X.
    Liu, S.
    Wu, L.
    Ma, L.
    Bi, L.
    Zuo, X.
    Sun, L.
    Huang, C.
    Tian, X.
    Li, M.
    Zhao, Y.
    Zeng, X.
    [J]. LUPUS, 2016, 25 (06) : 652 - 657
  • [5] Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus
    Li, M.
    Zhang, W.
    Leng, X.
    Li, Z.
    Ye, Z.
    Li, C.
    Li, X.
    Zhu, P.
    Wang, Z.
    Zheng, Y.
    Li, X.
    Zhang, M.
    Zhang, F.
    Zhao, Y.
    Zeng, X.
    [J]. LUPUS, 2013, 22 (11) : 1192 - 1199
  • [6] Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus
    Shi, Yue
    Bi, Dandan
    Wang, Yanhong
    Li, Ruofan
    Wu, Lijun
    Zhao, Cheng
    Wu, Zhenbiao
    Duan, Xinwang
    Xu, Jian
    Zhan, Feng
    Yang, Min
    Liu, Shengyun
    Li, Qin
    Zhang, Shuo
    Liu, Lingshan
    Zhao, Jiuliang
    Tian, Xinping
    Li, Xinying
    Wang, Qian
    Zeng, Xiaofeng
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [7] Chinese SLE Treatment and Research group (CSTAR) registry 2009-2019: Major clinical characteristics of Chinese patients with systemic lupus erythematosus
    Li, Mengtao
    Wang, Yanhong
    Zhao, Jiuliang
    Wang, Qian
    Wang, Ziqian
    Tian, Xinping
    Zeng, Xiaofeng
    [J]. RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2021, 2 (01): : 43 - 47
  • [8] Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
    Xiang, Yirong
    Li, Mengtao
    Luo, Hui
    Wang, Yanhong
    Duan, Xinwang
    Zhao, Cheng
    Zhan, Feng
    Wu, Zhenbiao
    Li, Hongbin
    Yang, Min
    Xu, Jian
    Wei, Wei
    Wu, Lijun
    You, Hanxiao
    Qian, Junyan
    Yang, Xiaoxi
    Huang, Can
    Zhao, Jiuliang
    Wang, Qian
    Leng, Xiaomei
    Tian, Xinping
    Zhao, Yan
    Zeng, Xiaofeng
    [J]. ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [9] Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
    Yirong Xiang
    Mengtao Li
    Hui Luo
    Yanhong Wang
    Xinwang Duan
    Cheng Zhao
    Feng Zhan
    Zhenbiao Wu
    Hongbin Li
    Min Yang
    Jian Xu
    Wei Wei
    Lijun Wu
    Hanxiao You
    Junyan Qian
    Xiaoxi Yang
    Can Huang
    Jiuliang Zhao
    Qian Wang
    Xiaomei Leng
    Xinping Tian
    Yan Zhao
    Xiaofeng Zeng
    [J]. Arthritis Research & Therapy, 23
  • [10] Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII
    Cheng Cheng
    Can Huang
    Zhen Chen
    Feng Zhan
    Xinwang Duan
    Yongfu Wang
    Cheng Zhao
    Zhenbiao Wu
    Jian Xu
    Hongbin Li
    Min Yang
    Rui Wu
    Jiuliang Zhao
    Shangzhu Zhang
    Qian Wang
    Xiaomei Leng
    Xinping Tian
    Mengtao Li
    Xiaofeng Zeng
    [J]. Arthritis Research & Therapy, 25